{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:32Z","timestamp":1753891952236,"version":"3.41.2"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold>The extensive utilisation of antiretroviral therapy has greatly improved the survival rates of those infected with human immunodeficiency virus (HIV). The objective of this study was to compare 3-drug regimens containing non-nucleoside reverse transcriptase inhibitor with 3-drug regimens containing integrase inhibitor (INI) regarding efficacy and safety in treatment-naive HIV-1-infected adults at 48 and 96\u00a0weeks, respectively.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>This study was a network meta-analysis using a Bayesian methodology. On January 8, 2020, we searched databases and other sources for randomized controlled trials conducted in treatment-naive HIV-1 adults and compared multiple 3-drug antiretroviral regimens containing INI, efavirenz (EFV), or rilpivirine (RPV). We extracted data on the following outcomes: virologic suppression, CD4<jats:sup>+<\/jats:sup>cell recovery, discontinuations, deaths, adverse events, serious adverse events, deaths related to study drugs, and drug-related adverse events. We conducted calculations within a Bayesian framework using R software.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>The network contained 15 randomized controlled trials including 9,745 patients. For efficacy outcomes, regimens containing INI, especially dolutegravir (DTG), were generally superior to other regimens. For virologic suppression at 48\u00a0weeks, odds ratios (95% credible intervals) were 0.6 (0.43, 0.82) for EFV+ tenofovir disoproxil fumarate (TDF)+emtricitabine (FTC) versus DTG+ abacavir+ lamivudine (3TC) and 0.52 (0.36, 0.75) for EFV+TDF+FTC vs. DTG+TDF+FTC\/3TC. For safety outcomes, regimens containing INI tended to be safer relative to regimens without INI. Outcomes associated with death were unsuitable for network meta-analysis due to low event rates.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>3-drug regimens containing INI demonstrate better efficacy and safety than those containing RPV or EFV.<\/jats:p>","DOI":"10.3389\/fphar.2021.603068","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T08:49:00Z","timestamp":1626857340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Ke","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meixia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-Positive Patients Starting Antiretroviral Therapy between 1996 and 2013: a Collaborative Analysis of Cohort Studies","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"B2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/apc.2013.0310","article-title":"Rilpivirine versus Efavirenz with Emtricitabine\/tenofovir Disoproxil Fumarate in Treatment-Naive HIV-1-Infected Patients with HIV-1 RNA <\/=100,000 copies\/mL: Week 96 Pooled ECHO\/THRIVE Subanalysis","volume":"28","author":"Behrens","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"B3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General Methods Formonitoring Convergence of Iterative Simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"Comput. Graph Stat."},{"key":"B4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir Plus Lamivudine versus Dolutegravir Plus Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-Naive Adults with HIV-1 Infection (GEMINI-1 and GEMINI-2): Week 48 Results from Two Multicentre, Double-Blind, Randomized, Non-inferiority, Phase 3 Trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"volume-title":"CADTH Canadian Drug Expert Committee Recommendation \u2013 BICTEGRAVIR\/EMTRICITABINE\/TENOFOVIR ALAFENAMIDE","year":"2018","key":"B5"},{"key":"B6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/1060028018761600","article-title":"Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data","volume":"52","author":"Capetti","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3851\/imp3270","article-title":"A Comparison between Two Dolutegravir-Based Two-Drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients","volume":"24","author":"Ciccullo","year":"2019","journal-title":"Antivir. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily Dolutegravir versus Darunavir Plus Ritonavir in Antiretroviral-Naive Adults with HIV-1 Infection (FLAMINGO): 48 Week Results from the Randomised Open-Label Phase 3b Study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus Efavirenz with Two Background Nucleoside or Nucleotide Reverse Transcriptase Inhibitors in Treatment-Naive Adults Infected with HIV-1 (THRIVE): a Phase 3, Randomised, Non-inferiority Trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and Safety of Rilpivirine (TMC278) versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results from the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials","volume":"60","author":"Cohen","year":"2012","journal-title":"J. Acquir Immune Defic Syndr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 Efficacy and Safety of Rilpivirine in Treatment-Naive, HIV-1 Patients in Two Phase III Randomized Trials","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"key":"B12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 Results from a Randomized Clinical Trial of Rilpivirine\/emtricitabine\/tenofovir Disoproxil Fumarate vs. Efavirenz\/emtricitabine\/tenofovir Disoproxil Fumarate in Treatment-Naive HIV-1-Infected Adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"B13","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking Consistency in Mixed Treatment Comparison Meta-Analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 Mg Efavirenz versus Standard 600 Mg Dose in HIV-Infected, Antiretroviral-Naive Adults (ENCORE1): a Randomised, Double-Blind, Placebo-Controlled, Non-inferiority Trial","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/s1473-3099(15)70060-5","article-title":"Efficacy and Safety of Efavirenz 400 Mg Daily versus 600 Mg Daily: 96-week Data from the Randomised, Double-Blind, Placebo-Controlled, Non-inferiority ENCORE1 Study","volume":"15","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"B17","unstructured":"Guidelines Version 10.02019"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/s0140-6736(17)32299-7","article-title":"Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection (GS-US-380-1489): a Double-Blind, Multicentre, Phase 3, Randomised Controlled Non-inferiority Trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/hiv.12643","article-title":"Comparison of 48-week Efficacies of Elvitegravir\/cobicistat\/emtricitabine\/tenofovir Alafenamide and Nucleoside\/nucleotide Reverse Transcriptase Inhibitor-Sparing Regimens: a Systematic Review and Network Meta-Analysis","volume":"19","author":"Gallien","year":"2018","journal-title":"HIV Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","article-title":"Life Expectancy in HIV-Positive Persons in Switzerland: Matched Comparison with General Population","volume":"31","author":"Gueler","year":"2017","journal-title":"AID"},{"key":"B21","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative Efficacy and Safety of First-Line Antiretroviral Therapy for the Treatment of HIV Infection: a Systematic Review and Network Meta-Analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J. Acquir Immune Defic Syndr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and Efficacy of Raltegravir-Based versus Efavirenz-Based Combination Therapy in Treatment-Naive Patients with HIV-1 Infection: a Multicentre, Double-Blind Randomised Controlled Trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-inferiority SWORD-1 and SWORD-2 Studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus Efavirenz with Tenofovir and Emtricitabine in Treatment-Naive Adults Infected with HIV-1 (ECHO): a Phase 3 Randomised Double-Blind Active-Controlled Trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily Dolutegravir versus Darunavir Plus Ritonavir for Treatment-Naive Adults with HIV-1 Infection (FLAMINGO): 96 Week Results from a Randomised, Open-Label, Phase 3b Study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"B31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3851\/imp2667","article-title":"96-Week Results of Abacavir\/lamivudine versus Tenofovir\/emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: ASSERT Study","volume":"18","author":"Moyle","year":"2013","journal-title":"Antivir. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1310\/hct1403-81","article-title":"Rilpivirine versus Efavirenz in HIV-1-Infected Subjects Receiving Emtricitabine\/tenofovir DF: Pooled 96-week Data from ECHO and THRIVE Studies","volume":"14","author":"Nelson","year":"2013","journal-title":"HIV Clin. Trials"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the Gap: Increases in Life Expectancy Among Treated HIV-Positive Individuals in the United States and Canada","volume":"8","author":"Okulicz","year":"2013","journal-title":"PLoS ONE"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1-Infected Patients: a Systematic Review and Network Meta-Analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized Comparison of Renal Effects, Efficacy, and Safety with Once-Daily Abacavir\/lamivudine versus Tenofovir\/emtricitabine, Administered with Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-week Results from the ASSERT Study","volume":"55","author":"Post","year":"2010","journal-title":"J. Acquir Immune Defic Syndr."},{"key":"B36","unstructured":"18R: A Language and Environment for Statistical Computing2019"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1097\/QAD.0000000000002285","article-title":"Comparative Efficacy and Safety and Dolutegravir and Lamivudine in Treatment Naive HIV Patients","volume":"33","author":"Radford","year":"2019","journal-title":"AIDS"},{"key":"B38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/s1473-3099(13)70257-3","article-title":"Once-daily Dolutegravir versus Twice-Daily Raltegravir in Antiretroviral-Naive Adults with HIV-1 Infection (SPRING-2 Study): 96 Week Results from a Randomised, Double-Blind, Non-inferiority Trial","volume":"13","author":"Raffi","year":"","journal-title":"Lancet Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily Dolutegravir versus Raltegravir in Antiretroviral-Naive Adults with HIV-1 Infection: 48 Week Results from the Randomised, Double-Blind, Non-inferiority SPRING-2 Study","volume":"381","author":"Raffi","year":"","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the Quality of Evidence from a Network Meta-Analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir versus Co-formulated Efavirenz, Emtricitabine, and Tenofovir for Initial Treatment of HIV-1 Infection: a Randomised, Double-Blind, Phase 3 Trial, Analysis of Results after 48 Weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380-1490): a Randomised, Double-Blind, Multicentre, Phase 3, Non-inferiority Trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate, Coformulated with Elvitegravir, Cobicistat, and Emtricitabine, for Initial Treatment of HIV-1 Infection: Two Randomised, Double-Blind, Phase 3, Non-inferiority Trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network Meta-Analysis: Application and Practice Using R Software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol. Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative Efficacy and Safety of Dolutegravir Relative to Common Core Agents in Treatment-Naive Patients Infected with HIV-1: a Systematic Review and Network Meta-Analysis","volume":"19","author":"Snedecor","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide for Initial Treatment of HIV-1 Infection: Week 96 Results from a Randomised, Double-Blind, Multicentre, Phase 3, Non-inferiority Trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"B25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-Based or Low-Dose Efavirenz\u2013Based Regimen for the Treatment of HIV-1","volume":"381","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B47","unstructured":"Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment: Guidance for Industry2015"},{"key":"B48","unstructured":"Gemtc: Network Meta-Analysis Using Bayesian Methods. R Package Version 0.8-2 ValkenhoefG. v. KuiperJ. 2016"},{"key":"B49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/QAD.0000000000000911","article-title":"Rilpivirine vs. Efavirenz-Based Single-Tablet Regimens in Treatment-Naive Adults: Week 96 Efficacy and Safety from a Randomized Phase 3b Study","volume":"30","author":"van Lunzen","year":"2016","journal-title":"AIDS"},{"key":"B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J. Acquir Immune Defic Syndr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir Plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir Combined with Emtricitabine and Tenofovir Alafenamide versus Dolutegravir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: Week 96 Results from a Randomised, Double-Blind, Multicentre, Phase 3, Non-inferiority Trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"B53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate, Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results","volume":"72","author":"Wohl","year":"2016","journal-title":"J. Acquir Immune Defic Syndr."},{"volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV infectionRecommendations for a Public Health Approach","year":"2016","key":"B54"},{"key":"B55","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A Randomized Double-Blind Comparison of Coformulated Elvitegravir\/cobicistat\/emtricitabine\/tenofovir Disoproxil Fumarate versus Efavirenz\/emtricitabine\/tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results","volume":"63","author":"Zolopa","year":"2013","journal-title":"J. Acquir Immune Defic Syndr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.603068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T17:51:24Z","timestamp":1725472284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.603068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":55,"alternative-id":["10.3389\/fphar.2021.603068"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.603068","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"article-number":"603068"}}